Preliminary Experience of Routine Voriconazole Therapeutic Drug Monitoring (TDM) in a Tertiary Care Centre
Information source: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Patients Treated With Voriconazole
Phase: N/A
Status: Completed
Sponsored by: Universitaire Ziekenhuizen Leuven Official(s) and/or principal investigator(s): Kim Vanstraelen, R.Ph., Principal Investigator, Affiliation: Catholic University of Leuven, Faculty of Pharmacy, division Hospital Pharmacy
Summary
The first goal of this study is to map all the subtherapeutic, therapeutic and
supratherapeutic voriconazole plasma levels in the University Hospitals Leuven. The second
objective is to optimize and validate guidelines for dose modifications in patients with too
low or high plasma concentrations and to investigate if the same guidelines can be used in
different patient populations.
Clinical Details
Official title: Preliminary Experience of Routine Voriconazole Therapeutic Drug Monitoring (TDM) in a Tertiary Care Centre.
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: Voriconazole plasma levels during routine intravenous and oral therapy
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients treated with voriconazole
- at least 1 voriconazole plasma level measured during therapy
Exclusion Criteria:
- none
Locations and Contacts
University Hospitals Leuven, Leuven, Vlaams-Brabant 3000, Belgium
Additional Information
Starting date: October 2010
Last updated: February 6, 2015
|